Journal article
Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy
CY Chiu, JJ Chang, AI Dantanarayana, A Solomon, VA Evans, R Pascoe, C Gubser, L Trautman, R Fromentin, N Chomont, JH McMahon, PU Cameron, TA Rasmussen, SR Lewin
Journal of Immunology | Published : 2022
Abstract
In people with HIV (PWH) on antiretroviral therapy (ART), immune dysfunction persists, including elevated expression of immune checkpoint (IC) proteins on total and HIV-specific T cells. Reversing immune exhaustion is one strategy to enhance the elimination of HIV-infected cells that persist in PWH on ART. We aimed to evaluate whether blocking CTL-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), T cell Ig domain and mucin domain 3 (TIM-3), T cell Ig and ITIM domain (TIGIT) and lymphocyte activation gene-3 (LAG-3) alone or in combination would enhance HIV-specific CD4+ and CD8+ T cell function ex vivo. Intracellular cytokine staining was performed using human PBMCs from ..
View full abstractRelated Projects (2)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by funds from an American Foundation for AIDS Research Impact Grant (109226-58-RGRL) , and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Delaney AIDS Research Enterprise to Find a Cure Collaboratory Grant (UM1AI126611-01) , and the National Health and MedicalResearch Council (NHMRC) (1135851 and 1149990) . S.R.L. is an NHMRC Practitioner Fellow.